Type 2 diabetes affects over 37 million Americans, and any therapeutic intervention with meaningful glycemic control warrants clinical attention. Cannabis compounds, particularly CBD, have demonstrated measurable effects on insulin sensitivity and inflammatory markers in preliminary studies, though the evidence base remains limited for definitive clinical recommendations.
Emerging research suggests certain cannabinoids may influence glucose metabolism through effects on insulin sensitivity, pancreatic beta-cell function, and systemic inflammation. Small-scale studies have shown CBD may reduce fasting insulin levels and improve HOMA-IR scores in some patients. The endocannabinoid system appears to play a role in metabolic regulation, though the specific mechanisms and optimal dosing remain poorly understood. Current evidence consists primarily of observational studies and small controlled trials, with no large-scale clinical data establishing efficacy or safety profiles for diabetic patients.
“I’ve seen promising preliminary signals in my practice, but we’re nowhere near having the evidence base to recommend cannabis as diabetes treatment. The mechanistic rationale is intriguing, but patients need proven therapies first — cannabis remains adjunctive at best until we have proper clinical trials.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This News item was assembled from structured source metadata and pipeline scoring.